Chardan Capital Weighs in on Ocugen FY2025 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of Ocugen in a research note issued on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will earn ($0.25) per share for the year. Chardan Capital currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. Chardan Capital also issued estimates for Ocugen’s FY2026 earnings at ($0.27) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Ocugen in a research note on Thursday, March 6th.

Ocugen Price Performance

Shares of NASDAQ:OCGN opened at $0.80 on Thursday. The firm has a market cap of $233.47 million, a price-to-earnings ratio of -4.44 and a beta of 3.88. The business has a 50-day simple moving average of $0.67 and a two-hundred day simple moving average of $0.84. Ocugen has a fifty-two week low of $0.52 and a fifty-two week high of $2.08. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). Ocugen had a negative return on equity of 154.75% and a negative net margin of 532.51%. The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. During the same period in the previous year, the firm posted ($0.03) EPS.

Hedge Funds Weigh In On Ocugen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd boosted its holdings in shares of Ocugen by 8.5% in the 4th quarter. XTX Topco Ltd now owns 254,995 shares of the company’s stock worth $205,000 after purchasing an additional 19,894 shares during the period. MetLife Investment Management LLC boosted its position in Ocugen by 36.4% in the 3rd quarter. MetLife Investment Management LLC now owns 89,508 shares of the company’s stock valued at $89,000 after buying an additional 23,877 shares during the period. Two Sigma Securities LLC boosted its holdings in shares of Ocugen by 92.9% in the fourth quarter. Two Sigma Securities LLC now owns 51,909 shares of the company’s stock valued at $42,000 after purchasing an additional 25,004 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Ocugen by 309.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company’s stock valued at $32,000 after purchasing an additional 30,120 shares during the period. Finally, ProShare Advisors LLC grew its position in shares of Ocugen by 66.7% during the 4th quarter. ProShare Advisors LLC now owns 80,613 shares of the company’s stock worth $65,000 after buying an additional 32,262 shares in the last quarter. 10.27% of the stock is owned by institutional investors.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.